Arizona
Psilocybin has mixed legal status in Arizona as of 17 Aug 2026.1
- Status changed at this review, and checked against 2 cited sources at this review.
1. What the law is
SB 1555 (2025, Chapter 231), approved by the Governor and filed with the Secretary of State on June 27, 2025: a conditional trigger law adding A.R.S. 36-2517.02, under which a pharmaceutical composition of crystalline polymorph psilocybin that is approved by the FDA and rescheduled by the DEA to a schedule other than Schedule I is a controlled substance for the purposes of the chapter and may be prescribed in this state. Under section 5 of the chapter that provision does not become effective unless the approval and a federal interim final rule under 21 U.S.C. 811(j) are in place on or before January 1, 2031. FY2026 state budget (via HB 2871 push): $5M for ibogaine clinical research. Earlier $5M whole-mushroom psilocybin PTSD clinical trial funding (2023).1
Arizona has a psilocybin prescription law that does nothing yet. SB 1555, Chapter 231 of 2025, signed June 27, 2025, added A.R.S. 36-2517.02, which would let an FDA-approved crystalline polymorph psilocybin be prescribed in the state, but only if it is also rescheduled out of Schedule I on or before January 1, 2031. Neither step has happened, so the section sits dormant. The research money is real: the FY2026 budget carries a $5 million ibogaine study appropriation. Psilocybin is otherwise a controlled substance here, with no access program.
Two tracks run in parallel here and neither one opens a door. The money came first: the state budget signed in May 2023 put $5 million into clinical trials of whole-mushroom psilocybin, naming post-traumatic stress disorder, depression and anxiety among the target conditions, and the trial began enrolling first responders and military veterans at the Scottsdale Research Institute in late 2025. The FY2026 budget added a further $5 million for an ibogaine clinical research grant. The law is SB 1555, Chapter 231, signed June 27, 2025. It would let Arizona practitioners prescribe psilocybin in FDA-approved crystalline polymorph form, but only if the federal Drug Enforcement Administration first moves the substance out of Schedule I by January 1, 2031. Until that happens the statute authorizes nothing, and if the deadline passes without federal action the authorization never takes effect. Psilocybin is otherwise a controlled substance in Arizona, with no decriminalization measure, therapeutic access program or licensing framework in effect.
Arizona is the clearest example of the research-and-trigger-law model: fund clinical evidence, pre-commit to federal outcomes, and build no state access system of the kind Oregon and Colorado operate. SB 1555 stakes medical access on federal rescheduling rather than state licensing. The approach parallels Texas, which has financed psychedelic research at larger scale but has not enacted a prescription trigger. Near-term prospects run through the legislature: the 2026 bills on MDMA trials, veteran psilocybin therapy, and additional ibogaine research stalled amid the April 2026 budget standoff and veto moratorium, leaving research appropriations as the state's only active psychedelic policy track.
2. Pending legislation
Introduced but not yet law. If a bill passes, this record changes with it.
SB 1542 (2026) would extend workers' compensation coverage to one course of midomafetamine treatment for firefighters and certified peace officers diagnosed with post-traumatic stress disorder, and would amend A.R.S. 36-2511 as amended by Laws 2025, chapter 231; note that 36-2511 is the nomenclature section, and the conditional psilocybin prescription provision sits at A.R.S. 36-2517.02, added by the same chapter. azleg.gov holds no Senate-engrossed version of the bill, so it did not pass the Senate. Two measures previously recorded here are unrelated legislation: SB 1060 (2026) concerns voter registration and HB 2486 (2026) concerns distressed residential property, per their introduced texts at azleg.gov, verified 16 August 2026. The wider 2026 session was not separately enumerated for other psilocybin bills, so nothing is asserted about bills beyond these three.
3. History
The laws behind today’s status, when each took effect, and every review since, in order.
Gov. Katie Hobbs signs the FY2024 state budget, which appropriates $5 million for clinical trials of whole-mushroom psilocybin targeting PTSD, depression, and anxiety, and establishes a psilocybin research advisory council.
SB 1555 (Chapter 231) signed April 22: a trigger law permitting FDA-approved crystalline polymorph psilocybin to be prescribed in Arizona only if the DEA reschedules psilocybin out of Schedule I by January 1, 2031. It has no current operative effect.
FY2026 state budget enacted with a $5 million appropriation, advanced through the HB 2871 push, for a grant funding clinical research on ibogaine for neurological conditions including traumatic brain injury and PTSD.
The state-funded whole-mushroom psilocybin PTSD trial launches at the Scottsdale Research Institute, enrolling police officers, firefighters, and military veterans under medical supervision.
2026 session bills (SB 1542, $10 million for MDMA trials for veterans and first responders; SB 1060, psilocybin therapy for veterans; HB 2486, ibogaine research) stall without passage as Gov. Hobbs imposes a blanket veto moratorium during the budget standoff.
Arizona's entry was missing SB 1555, a 2025 law that would let psilocybin be prescribed only if the FDA approves it first. The 2026 bills stalled and nothing new was enacted.
Arizona's pending-bill list named two bills that turned out to be about voter registration and residential property. Corrected against the legislature's own bill texts. The law itself is unchanged.
Arizona's trigger law was signed on 27 June 2025, not in April, and the provision that would allow psilocybin to be prescribed sits at a different section of the code than the entry named. Both are corrected from the enacted chapter text. The law itself is unchanged and still does nothing today.
4. Trials in Arizona
Interventional psilocybin trials with at least one study site in Arizona, drawn from ClinicalTrials.gov, EU CTIS, and ISRCTN. Registry data is reported by sponsors and shown as filed.
Recruiting, active, completed and closed add up to the 9 trials with a study site in Arizona, as of Aug 2026. Closed covers trials terminated, suspended, withdrawn or left unverified.
| Registry ID | Trial | Phase | Sponsor | Status | Started |
|---|---|---|---|---|---|
| NCT06992999 (opens in new tab) | Psilocybin for Treatment of OCD-2 (opens in new tab)Site at University of Arizona-Tucson, Tucson | Phase Phase 1/2 | Sponsor Francisco A Moreno | Status Not yet recruiting | Started |
| NCT07347405 (opens in new tab) | Psilocybin Whole Mushroom for the Treatment of Obsessive-compulsive Disorder. (opens in new tab)Recruiting at The Clinical and Translational Sciences Research Center, Tucson | Phase Phase 1 | Sponsor Francisco A Moreno | Status Recruiting | Started |
| NCT06793397 (opens in new tab) | A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder (opens in new tab)Recruiting at Lighthouse Psychiatry, Gilbert | Phase Phase 3 | Sponsor Cybin IRL Limited | Status Recruiting | Started |
| NCT06605105 (opens in new tab) | Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND) (opens in new tab)Site at Combined Research Orlando, Phoenix | Phase Phase 3 | Sponsor Cybin IRL Limited | Status Enrolling by invitation | Started |
| NCT07275970 (opens in new tab) | Safety and Preliminary Efficacy of Organic Whole Psilocybin-Containing Mushrooms to Treat Patients Suffering From PTSD (opens in new tab)Site at Scottsdale Research Institute, Scottsdale | Phase Phase 1 | Sponsor Scottsdale Research Institute | Status Active, not recruiting | Started |
| NCT06564818 (opens in new tab) | A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder (opens in new tab)Sites in Phoenix and Tucson | Phase Phase 3 | Sponsor Cybin IRL Limited | Status Active, not recruiting | Started |
| NCT05711940 (opens in new tab) | Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD (opens in new tab)Site at Lighthouse Psychiatry Scottsdale, Gilbert | Phase Phase 3 | Sponsor COMPASS Pathways | Status Active, not recruiting | Started |
| NCT05624268 (opens in new tab) | Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD (opens in new tab)Site at University of Arizona College of Medicine - Tuscon, Tuscon | Phase Phase 3 | Sponsor COMPASS Pathways | Status Completed | Started |
| NCT03300947 (opens in new tab) | Psilocybin for Treatment of Obsessive Compulsive Disorder (opens in new tab)Site at University of Arizona, Tucson | Phase Phase 1 | Sponsor University of Arizona | Status Completed | Started |
ClinicalTrials.gov data courtesy of the U.S. National Library of Medicine.
5. Common questions
Is psilocybin legal in Arizona?
Psilocybin has mixed legal status in Arizona as of 17 Aug 2026.
Are magic mushrooms ("shrooms") legal in Arizona?
"Magic mushrooms" and "shrooms" are common names for fungi that contain psilocybin. Psilocybin has mixed legal status in Arizona as of 17 Aug 2026. Some laws control the compound and the fungus separately, so this record states the position for psilocybin in Arizona.
Sources and confidence
Every status line is checked against the primary sources below. How each record is graded for confidence is set out in the methodology.
- 1.azleg.gov (opens in new tab) · azleg.gov
- 2.Marijuana Moment.Marijuana Moment (opens in new tab) · marijuanamoment.net
Cited at the review
This information is for educational purposes only and does not constitute legal advice. Laws change frequently, and enforcement practice can differ from the letter of the law. Verify current status with local authorities before relying on this record.
Changes to this record
Every change we have made to this record, dated, corrections included. Nothing changes silently.
Arizona's trigger law was signed on 27 June 2025, not in April, and the provision that would allow psilocybin to be prescribed sits at a different section of the code than the entry named. Both are corrected from the enacted chapter text. The law itself is unchanged and still does nothing today.
Arizona's pending-bill list named two bills that turned out to be about voter registration and residential property. Corrected against the legislature's own bill texts. The law itself is unchanged.
Arizona's entry was missing SB 1555, a 2025 law that would let psilocybin be prescribed only if the FDA approves it first. The 2026 bills stalled and nothing new was enacted.
Arizona: psilocybin legal status. The Psilocybin Record. Accession US-AZ-001. Status as of 17 Aug 2026. https://psilocybinlegalization.com/record/arizona
If this record changes, know first.
One email when Arizona's status changes.
No spam. Never shared. Unsubscribe anytime. Privacy statement